Global Breast Cancer Screening and Diagnostics Market, 2026-2036 | AI Imaging and Wider Screening Push Breast-Cancer Diagnostics Toward $12 Billion

Global Breast Cancer Screening and Diagnostics Market, 2026-2036 | AI Imaging and Wider Screening Push Breast-Cancer Diagnostics Toward $12 Billion Dublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Breast Cancer Screening and Diagnostics Market - A Global and Regional Analysis: Focus on Product, Application, End User, Regional, and Country-Level Analysis - Analysis and Forecast, 2026-2036" has been added to ResearchAndMarkets.com's offering.

The global breast cancer screening and diagnostics market is projected to grow from $5.50 billion in 2025 to $12.15 billion by 2036, representing a compound annual growth rate (CAGR) of 7.49% from 2026 to 2036. According to the report, market expansion is being driven by the rising incidence of breast cancer, stronger awareness of early detection, expanded screening programs, and continued innovation in diagnostic imaging, molecular testing, and artificial intelligence (AI).

Breast cancer remains the most commonly diagnosed cancer among women worldwide. The World Health Organization reported approximately 2.3 million diagnoses and nearly 670,000 deaths in 2022. This disease burden is increasing demand for digital mammography, digital breast tomosynthesis (3D mammography), breast ultrasound, magnetic resonance imaging (MRI), molecular breast imaging, contrast-enhanced mammography, biopsy technologies, genomic assays, and biomarker testing.

Technology Innovation Reshapes Breast Cancer Detection

Rapid advances in breast cancer screening and diagnostic technologies are improving lesion detection, clinical workflows, and treatment planning. Digital breast tomosynthesis, automated breast ultrasound systems (ABUS), breast MRI, AI-assisted image interpretation, next-generation sequencing (NGS), liquid biopsy, and gene expression profiling are supporting more precise patient evaluation. These technologies are particularly important for women with dense breast tissue or elevated genetic risk.

AI-enabled computer-aided detection (CAD) systems can improve image interpretation consistency and reduce radiologist reading times. At the same time, cloud-connected platforms, radiology information systems (RIS), picture archiving and communication systems (PACS), digital pathology, and predictive analytics are facilitating remote interpretation and integrated care. Portable imaging systems and mobile mammography programs are also expanding access in underserved communities.

Governments and healthcare organizations are strengthening organized screening initiatives across developed and emerging economies. The European Commission continues to encourage coordinated screening across member states, while the U.S., the U.K., Canada, Australia, and Japan are expanding population-based coverage. Favorable reimbursement policies and investments in women's health are supporting adoption, although affordability, workforce shortages, healthcare access disparities, and false-positive results remain important challenges.

Market Segmentation Highlights

The breast cancer screening and diagnostics market is segmented by product into imaging systems, diagnostic systems, and biopsy and guidance systems. Imaging systems held the leading market position in 2025 due to their role in routine detection and national screening programs. Strong procedure volumes, recurring equipment upgrades, dose optimization, improved image quality, and AI-assisted analysis continue to support this segment.

By application, the market includes screening, diagnosis, staging, treatment selection, prognosis and recurrence risk assessment, therapy monitoring, and post-treatment surveillance. Screening represented the dominant application in 2025, supported by routine mammography recommendations, public awareness initiatives, government programs, and broad adoption of digital mammography and 3D breast tomosynthesis.

Hospitals led the market by end user in 2025, ahead of diagnostic imaging centers and other end users. Their leadership reflects the ability to integrate screening, advanced imaging, biopsy, pathology, molecular testing, and multidisciplinary treatment planning within a single care setting.

North America remained the leading regional market, supported by advanced healthcare infrastructure, high healthcare expenditure, established screening programs, favorable reimbursement, and early adoption of AI-assisted imaging and molecular diagnostics. The presence of major companies, including Hologic, GE HealthCare, Becton, Dickinson and Company, and Danaher Corporation, also contributes to regional product development and commercialization. Europe and Asia-Pacific are expected to provide additional growth opportunities through screening expansion, infrastructure investment, and rising demand for precision diagnostics.

Market Drivers, Challenges, and Opportunities

Increasing breast cancer prevalence is a primary market driver because each suspected case can require multiple screening and diagnostic procedures. These may include mammography, tomosynthesis, ultrasound, MRI, image-guided biopsy, histopathology, hormone receptor testing, HER2 testing, and genomic risk assessment. In the U.S., the American Cancer Society estimates that approximately 321,910 new invasive breast cancer cases will be diagnosed among women in 2026, alongside about 60,730 cases of ductal carcinoma in situ.

High capital requirements remain a significant barrier, particularly in low- and middle-income countries. Digital mammography systems can cost between $50,000 and $265,000, while advanced digital breast tomosynthesis systems may exceed $250,000 before installation, maintenance, software, training, and operating costs. Limited availability of radiologists, pathologists, referral networks, and supporting IT infrastructure can further restrict adoption.

Expanding screening coverage and improving follow-up compliance represent major market opportunities. NHS breast screening uptake in the U.K. declined from 71.1% in 2018-19 to 64.6% in 2022-23, while participation among first-time invitees reached 53.7%. Digital appointment systems, automated invitations, integrated registries, patient outreach, and recall management tools could improve attendance and increase demand for downstream imaging, biopsy, pathology, and molecular testing services.

Recent Breast Cancer Diagnostics Developments

Competitive and Strategic Outlook

Competition is focused on imaging performance, lower radiation exposure, workflow automation, interoperability, AI integration, patient comfort, and precision oncology. Manufacturers are also introducing subscription-based software, maintenance programs, training services, and managed screening solutions to improve affordability and long-term customer engagement.

The report identifies collaboration among medical device manufacturers, biotechnology companies, healthcare providers, research institutions, and public health agencies as an important growth strategy. Geographic expansion, mobile screening services, cloud-based diagnostic platforms, and partnerships with government-led programs may help companies reach populations where screening participation remains low.

Prominent participants include Becton, Dickinson and Company, Canon Inc., FUJIFILM Corporation, GE HealthCare, Koninklijke Philips N.V., Hologic Inc., F. Hoffmann-La Roche Ltd, Seno Medical, Planmed Oy, and QIAGEN. These companies are investing in digital mammography, breast tomosynthesis, AI-powered software, biopsy systems, molecular diagnostics, and connected clinical platforms.

The report's findings are based on primary interviews with healthcare executives, manufacturers, radiology providers, hospitals, imaging centers, and screening programs, supported by annual reports, regulatory filings, company publications, recognized journals, industry databases, and other validated secondary sources. Market estimates cover 2024 through 2036, with 2025 as the base year and 2026 through 2036 as the forecast period.

Key Attributes:

Key Topics Covered:

Executive Summary

Scope and Definition

1 Global Breast Cancer Screening and Diagnostics Market: Industry Outlook

1.1 Market Trends

1.1.1 Impact Analysis

1.1.2 Integration of Artificial Intelligence

1.2 Regulatory Landscape

1.2.1 U.S.

1.2.2 Europe

1.2.3 Asia-Pacific

1.2.3.1 China

1.2.3.2 Japan

1.2.3.3 India

1.3 Market Dynamics

1.3.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment

1.3.2 Market Drivers

1.3.2.1 Increasing Prevalence of Breast Cancer

1.3.2.2 Expansion of Organized Screening Programs and Lower Screening Age Thresholds

1.3.2.3 Adoption of Digital Breast Tomosynthesis and Advanced Mammography Technologies

1.3.3 Market Challenges

1.3.3.1 High Capital Investment and Infrastructure Requirements

1.3.3.2 Uneven Screening Access and Low Follow-Up Compliance

1.3.4 Market Opportunities

1.3.4.1 Shift from Age-Based to Risk-Stratified, Personalized Screening

2 Product

2.1 Imaging System

2.2 Diagnostics System

2.3 Biopsy and Guidance Systems

3 Application

3.1 Screening

3.2 Diagnosis

3.3 Staging

3.4 Treatment Selection

3.5 Prognosis and Recurrence Risk Assessment

3.6 Therapy Monitoring

3.7 Post-Treatment Surveillance

4 End User

4.1 Hospitals

4.2 Diagnostic Imaging Centers

4.3 Other End Users

5 Region

5.1 Regional Summary

5.1.1 Regional Overview

5.1.2 Driving Factors for Market Growth

5.1.3 Factors Challenging the Market

5.1.4 Market Sizing and Forecast

5.2 North America

5.2.1 U.S.

5.2.2 Canada

5.3 Europe

5.3.1 U.K.

5.3.2 Germany

5.3.3 France

5.3.4 Italy

5.3.5 Spain

5.3.6 Rest-of-the- Europe

5.4 Asia Pacific

5.4.1 China

5.4.2 Japan

5.4.3 India

5.4.4 Australia

5.4.5 South Korea

5.4.6 Rest-of-the-Asia Pacific

5.5 Rest-of-the-World

6 Competitive Benchmarking and Company Profiles

6.1 Global Breast Cancer Screening and Diagnostics Market, Key Strategies and Developments, January 2023-April 2026

6.2 Key Developments Analysis (by Company), January 2023-June 2026

6.3 Company Profiles: Overview, Top Products, Top Competitors, Key Personnel, and Analyst View

6.3.1 Becton, Dickinson and Company

6.3.2 Canon

6.3.3 F. Hoffmann-La Roche Ltd

6.3.4 FUJIFILM Corporation

6.3.5 GE Healthcare

6.3.6 Hologic, Inc.

6.3.7 Koninklijke Philips N.V.

6.3.8 Seno Medical

6.3.9 Siemens Healthineers

6.3.10 Planmed Oy

6.3.11 QIAGEN

7 Research Methodology

7.1 Data Sources

7.1.1 Primary Data Sources

7.1.2 Secondary Data Sources

7.1.3 Data Triangulation

7.2 Market Estimation and Forecast

List of Figures [46]

List of Tables [3]

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/29d92f

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.